Navigation Links
U-M scientist to talk about tissue engineering at AAAS

Scientists have a pretty good handle on how to teach human cells to do tricks in a laboratory---things like getting soft cells from the mouth's lining to form bone.

But in the real world, accomplishing such feats is more complex. Regenerating the jaw bone of a person undergoing radiation therapy for cancer means managing the constant bacteria bath of a human mouth as well as compensating for the damage of radiation.

"It's not just a question of whether we can make new tissue in a perfect condition. Now we're mimicking what can really happen in a person, and we don't know if the rules of regeneration might be totally different," said Paul Krebsbach, associate professor at the U-M School of Dentistry.

Krebsbach is scheduled to participate in a panel titled "Tissue Engineering for the Head and Neck," at the AAAS annual meeting Feb. 17-21 in Washington, D.C. The tissue engineering panel is slated for Feb. 20 1:45-3:15 p.m.

In the broadest sense, tissue engineering refers to growing human tissue through artificial means.

Typically it involves harvesting a small sample of cells, treating them in the lab, then reintroducing the cells into a damaged area, like a jaw bone damaged too badly to simply heal on its own. A tiny scaffold helps direct the engineered cells to the right place, then dissolves once the cells begin to generate to fill in the wound.

"In certain kinds of defects, the body cannot heal itself and the body needs a jumpstart," Krebsbach said. To heal a large wound, like that created when a cancerous tumor is removed from the jaw, that often means taking a bone graft from someplace like the hip. That approach has problems both for the wound at the donor site and for the site where it is implanted.

In addition to discussing the sometimes-messy real world applications of tissue engineering, Krebsbach plans to talk at AAAS about the potential for combining seemingly unrelated therapies to improve the benefits of tissue engineering.

For example, parathyroid hormone is given to patients with osteoporosis, a condition in which bone quality declines leaving them fragile and prone to breaking. Parathyroid hormone stimulates bone growth in these patients, and Krebsbach sees potential to use it for similar gains in tissue engineering new bone.

Bone morphogenetic proteins help cells differentiate into specific kinds of bone, and encouraging cells to make more BMPs during tissue engineering also can ramp up the effects.

"Together these therapies can overcome compromised environments," he said. "Combining therapies can help us overcome some of the complications of current therapies, too."

These approaches are not yet being tested in humans, but Krebsbach said some small clinical trials are under consideration.

If the combination therapy approach works, Krebsbach said the next step would be working with engineers to develop anatomically correct scaffolding with the same curvature and contours of natural bones. That would help a patient develop new bone almost indistinguishable from nature's original equipment.

Many researchers at University of Michigan have focused their tissue engineering efforts on the head and neck, in part because U-M Dentistry plays a leading role in the effort. Dentists have a long tradition of finding ways to fill tooth cavities that will not heal on their own, Krebsbach said, and that has led to research in biomaterials, bone and connective tissue function, and then tissue engineering.

At Michigan, tissue engineering collaboration includes dentists, M.D.s and engineers, among others. They all bring a different perspective, and it leads to scientific advances that couldn't happen in any one discipline, Krebsbach said.

"That's the beauty of tissue engineering. It has to be multi-disciplinary to work," he said.


'"/>

Source:University of Michigan


Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
3. UAB scientists discover the origin of a mysterious physical force
4. Fox Chase Cancer Center scientists identify immune-system mutation
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. U-M scientists find genes that control growth of common skin cancer
7. NC State scientist finds soft tissue in T. rex bones
8. UCLA scientists transform HIV into cancer-seeking missile
9. RNA project to create language for scientists worldwide
10. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals
11. To control germs, scientists deploy tiny agents provocateurs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2017)... -- GCE Solutions, a global clinical research organization (CRO), announces the launch ... October 4, 2017. Shadow is designed to assist medical writers and ... of the European Medicines Agency (EMA) in meeting the requirements for ... ... ...
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
Breaking Biology Technology: